Posters for pharmacies, 2023Canadian Pharmacists Association & The CART Access ProjectLink: [cpha-poster](CPHA5) What to expect when ending a pregnancy at home, 2023Canadian Pharmacists Association & The […]
Toolkits for Addressing Abortion Concerns
Debunking medication abortion myths, 2023Canadian Pharmacists Association & The CART Access ProjectLink: [cpha-debunking-myth](CPHA3) The Abortion options: A value clarification guide for health care professionals, 2005National Abortion […]
Product Monographs, Guidelines and Protocols
Health Canada MIFISO product monograph, 2022Linepharma International LimitedLink: [hres.ca](C17-2) Medical abortion, 2016Journal of Obstetrics and Gynaecology CanadaLink: [sogc-ma](C14) Canadian protocol for the provision of medical abortion via […]
Training and Webinars
SOGC’s medical abortion training program, 2024Link: sogc-training NAF Canada’s medication abortion training for primary care providers, 2023Link: nafc-training Case-based quizzes on medication abortion for pharmacistsLink: pharmacy5in5
Checklists and Resource Guides
A road map for all pharmacists, 2023Canadian Pharmacists Association & The CART Access ProjectLink: [cpha-roadmap](CPHA2) Pharmacist resource guide for medical abortion, 2018Judith Soon & Nevena Rebic; […]
Facility Setup
Below is a general guide of the steps to be taken when initiating medication abortion (MA) services at your pharmacy. Some of these may not […]
Clinical assessments
Prescribers will provide clinical assessments prior to prescribing MIFE / MISO. With the new guideline by SOGC for the provision of medical abortion via telemedicine (MA), prescribers […]
Pharmacokinetics
MIFE taken orally shows non-linear pharmacokinetics. It is rapidly absorbed and distributed, reaching peak concentrations after 0.75 hours. It is 94-99% plasma-bound and is metabolized […]
Drug interactions
MIFE is metabolized by CYP3A4 and is also an irreversible competitive inhibitor of CYP3A4 and, to a lesser extent, of CYPs 1A, 2B, 2D6 and […]
Optional follow-up
Patients are required to have a follow-up consultation with prescribers. A follow-up with dispensers is optional and can take place 2 – 3 days after MISO administration. […]